Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Serratus posterior superior intercostal plane block for Serratus Posterior Superior Intercostal Plane Block (SPSIPB)

This study will see if the serratus posterior superior intercostal plane (SPSIP) block improves postoperative recovery after breast cancer surgery. you would be randomly assigned to one of two groups.

Official registry: https://clinicaltrials.gov/study/NCT07843212 · Mucahide Emine Fidancı Kuas · enrollment listed as 80

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Serratus posterior superior intercostal plane block, or Sham SPSIP Procedure. The registry lists allocation as randomized. This study will see if the serratus posterior superior intercostal plane (SPSIP) block improves postoperative recovery after breast cancer surgery.

They plan to enroll about 80 people at Çorum. Taking part typically means a procedure as part of the study plus check-ins.

Official title (unrewritten)

Effects of Serratus Posterior Superior Intercostal Plane Block on Perioperative Inflammatory Response and TLR4-Mediated Innate Immune Activation in Breast Cancer Surgery: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial

Interventions: Serratus posterior superior intercostal plane block, Sham SPSIP Procedure

Primary outcome (registry wording): Change in serum TLR4 concentration from baseline to 24 hours after surgery

Who it is for (from inclusion criteria)

  • Ages 18 Years to 85 Years
  • Women only
  • Female patients aged 18 to 85 years
  • Scheduled for elective breast cancer surgery under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III

Public study contact (from the registry)

Mucahide Emine Fidancı Kuas, MD

+90-553-204-9918

efidanci02@gmail.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingPhase 2Bethesda, Maryland
Phase 2: testing Pembrolizumab (Keytruda) for Metastatic Colorectal Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.

NCT01174121 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT07843212 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07843212?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07843212?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary